ethyl 5-(pyridin-3'-yl)penta-2,4-dienoate | 78775-01-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 5-(pyridin-3'-yl)penta-2,4-dienoate
• 英文别名: Ethyl 5-(pyridin-3-yl)-2,4-pentadienoate；ethyl 5-pyridin-3-ylpenta-2,4-dienoate
• CAS: 78775-01-6
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: WGSMUXGSKWSTAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 5-(pyridin-3'-yl)penta-2,4-dienoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以99%的产率得到5-(吡啶-3-基)戊酸乙酯
  参考文献：
  名称：

  通过烟碱取代的酯和酮的烯醇化物的脱芳基化环化，稠合双环哌啶和二氢吡啶。

  摘要：

  酮或酯的甲硅烷基烯醇醚衍生物通过烃或醚键连接到吡啶环的 3-位，一旦通过添加氯甲酸甲酯活化（作为酰基吡啶鎓物质），该环就会发生脱芳基亲核攻击。双环二氢吡啶产物在某些情况下不稳定，但在氢化后可以作为稠合双环哌啶分离。

  DOI：

  10.3762/bjoc.6.22
• 作为产物：
  描述：

  3-吡啶甲醛 、 4-(diethoxyphosphoryl)-but-2-enoic acid ethyl ester 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.75h， 以98%的产率得到ethyl 5-(pyridin-3'-yl)penta-2,4-dienoate
  参考文献：
  名称：

  通过烟碱取代的酯和酮的烯醇化物的脱芳基化环化，稠合双环哌啶和二氢吡啶。

  摘要：

  酮或酯的甲硅烷基烯醇醚衍生物通过烃或醚键连接到吡啶环的 3-位，一旦通过添加氯甲酸甲酯活化（作为酰基吡啶鎓物质），该环就会发生脱芳基亲核攻击。双环二氢吡啶产物在某些情况下不稳定，但在氢化后可以作为稠合双环哌啶分离。

  DOI：

  10.3762/bjoc.6.22

文献信息

• Novel 1,8-naphthyridin-2(1h)-one derivatives
  申请人：——

  公开号：US20030036651A1

  公开（公告）日：2003-02-20

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R 1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R 2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  本发明的目的是提供具有强效抗哮喘特性和良好安全性的选择性PDE IV抑制剂。化合物的式子为（1）：其中：A是未取代或可选取代的5或6成员杂芳基或融合苯环，其中任何上述定义的杂芳基与苯环融合；B是碳或氮；R1是氢、低级烷基、三氟甲基、羟基、低级烷氧基、从羧酸或其衍生物得到的残基、氨基或含氨基氮的基团；R2是氢、卤素、氰基、硝基、低级烷基硫基、低级烷基亚砜基、低级烷基磺酰基、三氟甲基、羟基、低级烷氧基、从羧酸或其衍生物得到的残基、氨基或含氨基氮的基团；m是1到8的整数，均包括在内；或其药学上可接受的盐具有选择性的PDE IV抑制作用，并且可用作药物，优选为抗哮喘药物等。
• Pde IV inhibitors
  申请人：——

  公开号：US20040176365A1

  公开（公告）日：2004-09-09

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  这段话的目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。式(1)的化合物：其中A是亚甲基，低碳基亚甲基，羰基等，Y是含有氮、硫和氧中的一种或两种杂原子的5-或6成员杂芳基团，Z是i）融合环，其中任何5-或6成员杂芳基团融合到苯环中，或ii）苯基，可以是未取代或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员，但当A是亚甲基时，Y是从吡咯基，吡啶基等中选择的5-或6成员杂芳基团，Z是未取代或取代的苯基时，所述苯基上的取代基是氨基或含氨基氮的基团；或其药学上可接受的盐，具有优异的PDE IV抑制作用，是一种有用的药物，首选是抗哮喘药物等。
• PDE IV inhibitors
  申请人：Aska Pharmaceuticals Co., Ltd.

  公开号：US07115623B2

  公开（公告）日：2006-10-03

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  本发明旨在提供具有强效抗哮喘特性和优良安全性的选择性PDE IV抑制剂。化合物的结构式（1）：其中A为亚甲基，低碳基亚甲基，羰基等，Y为含有一或两个从氮，硫和氧中选择的杂原子的5或6元杂芳基基团，Z为i）融合环，其中任何5或6元杂芳基团融合到苯环上，或ii）苯基，可以是未取代的或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员所选择的，但当A为亚甲基，Y为从吡咯基，吡啶基等所选择的5或6元杂芳基团，Z为未取代或取代的苯基时，所述苯基上的取代基为氨基或含氨基氮的基团; 或其药学上可接受的盐，具有出色的PDE IV抑制作用，并且作为药物，特别是抗哮喘药物等非常有用。
• 1,8-naphthyridin-2(1H)-one derivatives
  申请人：Grelan Pharmaceutical Co., Ltd.

  公开号：US06642250B2

  公开（公告）日：2003-11-04

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  本文的目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。化合物的公式（1）如下：其中：A是未取代或可选择取代的5或6元杂环基或融合苯环，其中上述任何杂环基都与苯环融合；B是碳或氮；R1是氢、低碳基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或含氨基氮的基团；R2是氢、卤素、氰基、硝基、低烷基硫基、低烷基亚砜基、低烷基磺酰基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或含氨基氮的基团；m是1至8的整数，包括1和8；或其药学上可接受的盐具有选择性的PDE IV抑制作用，并且可用作药物，优选用作抗哮喘药物等。
• Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives
  作者：Tadao Tanouchi、Masamori Kawamura、Isao Ohyama、Ikuo Kajiwara、Yohichi Iguchi、Takanori Okada、Tsumoru Miyamoto、Ken Taniguchi、Masaki Hayashi

  DOI：10.1021/jm00142a006

  日期：1981.10

  The enzyme thromboxane (TX) synthetase is inhibited by pyridine. The beta-substituted pyridine derivatives showed higher inhibitory potency than the gamma-substituted ones having the same side chain. Among the beta-substituted derivatives containing the omega-carboxyalkyl group, the compounds with 6-8 carbon atoms in the side chain were especially effective. The derivatives holding the phenylene group in the side chain exhibited much higher inhibitory activity than those of the alkylene type. Among them, (E)-3-[4-(3-pyridylmethyl)phenyl]-2-methylacrylic acid hydrochloride (5a) had the highest potency (IC50 = 3 x 10(-9) M). The beta-substituted pyridine derivatives and 1-substituted imidazole derivatives which had the same side chain showed almost the same potency. The beta-substituted pyridine derivatives do not inhibit arachidonic acid cyclooxygenase or prostaglandin I2 synthetase, two other enzymes of the arachidonic cascade.